Dyadic International (DYAI) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed NewcelX (NCEL) over the past year, losing 60.7% versus a loss of 83.3%. Over five years, DYAI leads with a -90.8% price change compared with -99.7% for NCEL. Dyadic International is the larger company by market cap ($17.8 million vs $17.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | NCEL |
|---|---|---|
| Share price | $0.4441 | $3.05 |
| Market cap | $17.79M | $17.59M |
| 1-day change | -0.07% | -2.09% |
| YTD return | -52.72% | +63.68% |
| 1-year return | -60.67% | -83.32% |
| 5-year return | -90.84% | -99.68% |
| P/E ratio (TTM) | — | 5.86 |
| EPS (TTM) | $-0.23 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $18.60 |
| 52-week low | $0.34 | $1.83 |
| Distance from 52-week high | -72.24% | -83.63% |
| Analyst consensus | none | none |
| Avg. price target upside | +1138.46% | +655.34% |
| Average volume | 201.91K | 10.28K |
| Shares outstanding | 40.06M | 5.78M |
| Employees | 5 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed NCEL by 22.7 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
DYAI vs NCEL FAQ
Which is bigger, Dyadic International or NewcelX?
Dyadic International (DYAI) is larger, with a market capitalization of $17.79M compared with $17.59M for NewcelX (NCEL).
Which stock has performed better over the past year, DYAI or NCEL?
DYAI returned -60.67% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and NewcelX in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Dyadic International and Biotechnology: Pharmaceutical Preparations for NewcelX.